Abstract
DNA topoisomerase II (Top2) is essential for all eukaryotic cells in the regulation of DNA topology through the generation of temporary double-strand breaks. Cancer cells acquire enhanced Top2 functions to cope with the stress generated by transcription and DNA replication during rapid cell division since cancer driver genes such as Myc and EZH2 hijack Top2 in order to realize their oncogenic transcriptomes for cell growth and tumor progression. Inhibitors of Top2 are therefore designed to target Top2 to trap it on DNA, subsequently causing protein-linked DNA breaks, a halt to the cell cycle, and ultimately cell death. Despite the effectiveness of these inhibitors, cancer cells can develop resistance to them, thereby limiting their therapeutic utility. To maximize the therapeutic potential of Top2 inhibitors, combination therapies to co-target Top2 with DNA damage repair (DDR) machinery and oncogenic pathways have been proposed to induce synthetic lethality for more thorough tumor suppression. In this review, we will discuss the mode of action of Top2 inhibitors and their potential applications in cancer treatments.
Funder
Canadian Institute of Health Research
Subject
Drug Discovery,Pharmaceutical Science,Molecular Medicine
Reference163 articles.
1. Topoisomerases as Anticancer Targets;Delgado;Biochem. J.,2018
2. Topoisomerases and Cancer Chemotherapy: Recent Advances and Unanswered Questions;Bjornsti;F1000Research,2019
3. Synthetic Lethality as an Engine for Cancer Drug Target Discovery;Huang;Nat. Rev. Drug Discov.,2020
4. PARP Inhibitors: Review of Mechanisms of Action and BRCA1/2 Mutation Targeting;Dziadkowiec;Prz. Menopauzalny,2016
5. A Moving Target: Structure and Disorder in Pursuit of Myc Inhibitors;Bayliss;Biochem. Soc. Trans.,2017
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献